PaulJ.ShamiMD
Hematology • Salt Lake City, UTHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Professor, Internal Medicine, University of Utah School of Medicine
Dr. Shami is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1950 Circle of Hope Dr
Salt Lake City, UT 84112Phone+1 801-581-2121
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1994- Duke University HospitalResidency, Internal Medicine, 1988 - 1991
American University of Beirut Faculty of MedicineClass of 1988
Certifications & Licensure
UT State Medical License 1997 - 2026
NC State Medical License 1991 - 1999
MD State Medical License 1990 - 1991- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Start of enrollment: 2008 Mar 01
- Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Start of enrollment: 2011 Feb 01
- Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
- Join now to see all
Publications & Presentations
PubMed
- Tattoos and Risk of Hematologic Cancer: A Population-Based Case-Control Study in Utah.Rachel D McCarty, Britton Trabert, David Kriebel, Morgan M Millar, Brenda M Birmann
Cancer Medicine. 2024-10-01 - 1 citationsAcute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.Bijal Shah, Ryan J Mattison, Ramzi Abboud, Peter Abdelmessieh, Ibrahim Aldoss
Journal of the National Comprehensive Cancer Network. 2024-10-01 - Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy.M Tommy Gambles, Shannuo Li, Isaac Kendell, Jiahui Li, Douglas Sborov
ACS Nano. 2024-08-27
Abstracts/Posters
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master TrialPaul J Shami, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Durham’s Chimerix Pays $30M to Secure Rights for Late-Stage Leukemia DrugAugust 2nd, 2019
Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid LeukemiaJuly 31st, 2019
Huntsman Cancer Institute Joins Study Aimed at Improving Leukemia Screening, TreatmentMarch 19th, 2018- Join now to see all
Grant Support
- Preclinical Development Of JS-K, A Novel No-Generating Prodrug For CancerNational Cancer Institute2010–2012
- Development Of JS-K As An Anti-Leukemic AgentNational Cancer Institute2008–2012
- Role Of Nitric Oxide In Myelodysplastic SyndromesNational Center For Research Resources2005
- Genetic Targets Of Nitric Oxide In Leukemia CellsNational Cancer Institute2002–2004
- NO, Guanylate Cyclase And Immunotherapy Of CancerNational Cancer Institute2000
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
